Welcome to our dedicated page for ACCUSTEM SCIENCES news (Ticker: ACUT), a resource for investors and traders seeking the latest updates and insights on ACCUSTEM SCIENCES stock.
AccuStem Sciences Inc (ACUT) is a biotechnology innovator advancing stem cell research and regenerative medicine solutions. This page provides investors and industry professionals with direct access to the company's official announcements, financial updates, and scientific developments.
Track ACUT's progress through curated press releases covering clinical trial milestones, regulatory filings, and strategic partnerships. Our repository ensures you stay informed about advancements in cellular therapies and biotechnological innovations without speculative commentary.
Discover updates across key categories including quarterly earnings reports, intellectual property developments, and collaborative research initiatives. Each entry is timestamped for reference and formatted for clarity across devices.
Bookmark this page for streamlined access to AccuStem's evolving story in medical science. Verify critical information directly from primary sources before making data-driven decisions.
AccuStem Sciences (OTCQB: ACUT) has acquired the license for the proprietary microRNA Signature Classifier (MSC) test, a blood-based lung cancer screening technology. The test, developed by researchers at Istituto Nazionale Tumori (INT), evaluates 24 micro RNAs to enhance the accuracy of low-dose computed tomography (LDCT) in patients with pulmonary nodules.
Published data demonstrates that patients who test positive for both MSC and LDCT have a 30-fold higher cumulative lung cancer incidence compared to those negative for both tests. The combination of MSC with LDCT shows a five-fold reduction in false positives versus LDCT alone, potentially leading to improved outcomes and reduced healthcare costs.
The acquisition terms include issuing 3,750,000 common shares of AccuStem, with a 13-month resale restriction period. The company plans to launch the MSC test in the US in 2026.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, has announced that its Board Chairman, Gabriele Cerrone, has acquired an additional 100,000 ACUT shares through open market purchases. Following this transaction, Cerrone's total shareholding has increased to 4,719,957 shares.
AccuStem Sciences (OTCQB: ACUT) announced that its Chairman, Gabriele Cerrone, has acquired an additional 24,500 shares, bringing his total ownership to 3,855,723 shares. This purchase reflects the Chairman's confidence in the company’s future, as AccuStem focuses on developing innovative molecular testing for cancer diagnostics aimed at improving patient outcomes. The company is dedicated to addressing critical clinical needs throughout cancer screening, treatment, and monitoring.
AccuStem Sciences, Inc. (OTCQB: ACUT) announced the appointment of Sean McDonald to its Board of Directors, increasing the board to five members. McDonald brings extensive experience in building healthcare organizations and securing funding for early-stage companies. Currently the CEO of Ocugenix, he previously held leadership roles at Precision Therapeutics and Automated Healthcare. His background will support AccuStem's mission to innovate cancer diagnostics through genomic testing. CEO Wendy Blosser expressed confidence in McDonald's ability to advance the company's growth strategy.
FAQ
What is the current stock price of ACCUSTEM SCIENCES (ACUT)?
What is the market cap of ACCUSTEM SCIENCES (ACUT)?
